Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Long-term follow-up study of sustained biochemical responders with interferon therapy.

Shindo M, Hamada K, Oda Y, Okuno T.

Hepatology. 2001 May;33(5):1299-302.

PMID:
11343259
2.

Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.

Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S89-91.

PMID:
16234069
4.
5.

Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.

Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T, Nakano S, Hayashi K, Katano Y, Nakano I, Hayakawa T, Nishimura D, Kato K, Imada K, Imoto M, Fukuda Y; Yon-Ken HCV-HCC Follow-up Study Group.

J Viral Hepat. 2000 Nov;7(6):414-9.

PMID:
11115052
6.

Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C.

Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A, Borzio M, Solforosi L, Morabito A, Ideo G, Podda M.

J Hepatol. 2001 May;34(5):748-55.

PMID:
11434622
7.

Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.

De Mitri MS, Morsica G, Chen CH, Mele L, Baccarini P, Chianese R, Piccinini A, Lazzarin A, Pisi E.

Ital J Gastroenterol Hepatol. 1997 Jun;29(3):255-61.

PMID:
9646218
8.

Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death.

Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, Tanaka E, Hino K, Hayashi K, Tamura S, Itoh Y, Kiyosawa K, Kakumu S, Okita K, Hayashi N.

J Viral Hepat. 2004 Mar;11(2):148-56.

PMID:
14996350
9.

Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.

Hino K, Kitase A, Satoh Y, Fujiwara D, Yamaguchi Y, Korenaga M, Shingai Y, Konishi T, Yamashita S, Uchida K, Mori K, Hanada H, Kodama T, Nukui K, Okita K.

J Viral Hepat. 2002 Sep;9(5):370-6.

PMID:
12225332
10.

Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.

Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, Kaneko M, Goto I, Tanaka N, Arakawa Y.

Liver Int. 2005 Feb;25(1):85-90.

PMID:
15698403
11.

Long-term course of interferon-treated chronic hepatitis C.

Cammà C, Di Marco V, Lo Iacono O, Almasio P, Giunta M, Fuschi P, Vaccaro A, Fabiano C, Magrin S, Di Stefano R, Bonura C, Pagliaro L, Craxì A.

J Hepatol. 1998 Apr;28(4):531-7.

PMID:
9566819
12.

Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis.

Suzuki K, Ohkoshi S, Yano M, Ichida T, Takimoto M, Naitoh A, Mori S, Hata K, Igarashi K, Hara H, Ohta H, Soga K, Watanabe T, Kamimura T, Aoyagi Y.

Liver Int. 2003 Jun;23(3):143-7.

PMID:
12955876
13.

Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.

Testino G, Ansaldi F, Andorno E, Ravetti GL, Ferro C, De Iaco F, Icardi G, Valente U.

Hepatogastroenterology. 2002 Nov-Dec;49(48):1636-8.

PMID:
12397752
14.

Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.

Pramoolsinsap C, Poovorawan Y, Sura T, Theamboonlers A, Busagorn N, Kurathong S.

Southeast Asian J Trop Med Public Health. 1998 Sep;29(3):480-90.

PMID:
10437943
15.

Clinical outcome of chronic hepatitis C in patients treated with interferon: comparison between responders and non-responders.

Morisco F, Marmo R, Iasevoli P, Sessa G, Tuccillo C, Del Vecchio Blanco C, Caporaso N.

Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):454-8.

PMID:
10575561
16.

Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy.

Larghi A, Tagger A, Crosignani A, Ribero ML, Bruno S, Portera G, Battezzati PM, Maggioni M, Fasola M, Zuin M, Podda M.

J Med Virol. 1998 May;55(1):7-11.

PMID:
9580879
17.
18.

The impact of antiviral therapy on the course of chronic HCV infection. A systematic review.

Almasio PL, Venezia G, Craxì A.

Panminerva Med. 2003 Sep;45(3):175-82. Review.

PMID:
14618115
19.

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M.

Ann Intern Med. 1999 Aug 3;131(3):174-81.

PMID:
10428733
20.

Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon.

Kojima H, Hongo Y, Harada H, Inoue T, Miyaji K, Kashiwagi M, Momose T, Arisaka Y, Fukui H, Murai S, Tokita H, Kamitsukasa H, Yagura M, Katsu K.

J Gastroenterol Hepatol. 2001 Sep;16(9):1015-21.

PMID:
11595066

Supplemental Content

Support Center